Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Earnings for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Earnings in 2023 (TTM): $-409,551,000
According to Biohaven Pharmaceutical Holding Company Ltd.'s latest financial reports the company's current earnings (TTM) are $-409,551,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Biohaven Pharmaceutical Holding Company Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-409,551,000 | $-408,168,000 |
| 2022 | $-569,841,000 | $-570,279,000 |
| 2021 | $-212,430,000 | $-213,796,000 |
| 2020 | $-118,668,000 | $-118,668,000 |
| 2019 | $-528,386,000 | $-528,805,000 |
| 2017 | $ | $ |